Navigation Links
Acacia Pharma Initiates Phase II Study With APD403 in Chemotherapy Induced Nausea & Vomiting (CINV)
Date:10/30/2013

CAMBRIDGE, England, October 30, 2013 /PRNewswire/ --

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications.

CINV occurs in approximately 70% of all cancer patients receiving chemotherapy and in 90% of those receiving highly emetogenic chemotherapy (HEC). It is one of the major side effects of cancer therapy and a considerable concern for patients. There are two major types of CINV, referred to as acute CINV which occurs on the day of treatment, and delayed CINV which occurs up to five days following chemotherapy. Despite the improvements in managing CINV there remains a clear unmet need to reduce the incidence of nausea, especially in delayed CINV, as standard regimens are relatively effective at stopping patients being sick (vomiting) but much less so at stopping them feeling sick (nausea), which is often the most distressing symptom.

The Phase II study is taking place in around 25 major centres in the UK, Denmark, Germany and the USA and aims to recruit 315 cancer patients receiving HEC. The trial compares 3 doses of APD403 against placebo in the delayed phase of CINV. The primary endpoint is no vomiting or retching and no requirement for anti-emetic rescue medication for 5 days after the start of chemotherapy administration. The incidence and severity of nausea is being studied as a secondary endpoint.

Acacia Pharma has previously generated positive Phase IIa clinical data when the drug was given prophylactically to cancer patients being treated with the HEC, cisplatin. These data showed APD403 has t
'/>"/>

SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
2. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 10 Inclinix, Inc., an,enrollment contract research organization ... today that it has received a patent,for its ... system that guides,interview questions during patient qualification for ... Inclinix advertises to recruit patients into clinical trials.,Respondents ...
... LC STAR nebulizer and,PRONEB Ultra II compressor ... (Nasdaq: ISPH ) second Phase 3 ... treatment. PARI reusable nebulizers are,considered the gold ... in,commercial sales including AstraZeneca,s Pulmicort Respules, Sepracor,s,Xopenex ...
Cached Medicine Technology:Inclinix Announces New Patent for Expert System Platform 2PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial 2
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... taking a traditional Indian remedy for piles known as Endopile ... test of the drug, following a complaint, had revealed harmful ... been recalled from the Singapore market. The HSA said the ... ,The complaint came from a hospital that had treated a ...
... acids is claimed to prevent more sudden deaths ... even implanted defibrillators according to US scientists.// ... compared such preventive strategies by food supplementation and ... 100,000 people that resembled the population of Olmsted ...
... in the US do not wash their hands properly.// ... had conducted the survey of 8,000 people in eight countries. ... around U.S., U.K., Italy, Germany, United Arab Emirates, India, Malaysia, ... disinfectants, mouthwash, and cleaning products. In their survey they had ...
... and made available on the World Wide Web - a ... in the body. // ,The researchers had earlier identified ... surface of cells called cilia as such a common link. ... have links associated with the tiny, hair-like cilia and implications ...
... The State University of New Jersey have modified a ... stroke patients. The game helps with hand// exercises and ... effective that similar systems, which are more expensive. The ... stroke rehabilitation. ,Virtual rehabilitation gives therapists new ...
... St. Louis and other institutions have reported that experimental ... (PXR) my help in the treatment of Niemann-Pick type ... that is often fatal within the first two decades ... model for Niemann-Pick type C (NPC) disease showed that ...
Cached Medicine News:Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3Health News:Stroke Rehabilitation Through Modified Video Games 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: